PHYSICIAN RESOURCES

CSL Behring provides a broad range of resources and materials
to assist physicians in the treatment of Alpha-1.

Continuing education

The Alpha-1 Foundation offers a CME program to help educate healthcare professionals on the standards for the diagnosis and management of Alpha-1.

Important Alpha-1 links

The Zemaira CareZ® community includes a network of not-for-profit organizations and advocacy groups that may be able to provide additional Alpha-1 assistance. In particular, CareZ works closely with AlphaNet to provide your patients ongoing monthly support from fellow Alphas.

Other helpful links

  • The Alpha-1 Foundation
    Works closely with multiple agencies and the pharmaceutical industry to expedite the development of improved therapies. With the overriding goal of curing Alpha-1, the Alpha-1 Foundation has invested almost $47 million to support alpha-1 antitrypsin deficiency research and programs at 94 institutions in North America, Europe, the Middle East, and Australia.
  • Alpha-1 Genetic Counseling Center
    Free tests are available to determine if your patient’s blood relatives have Alpha-1, regardless of whether they are showing symptoms. Family members of Alpha-1 patients are encouraged to call the Alpha-1 Genetic Counseling Center at 1-800-785-3177 to learn more about the importance of testing for Alpha-1.
  • The American Thoracic Society
    Focuses on respiratory and critical care medicine, with a long-range goal of decreasing morbidity and mortality from respiratory disorders and life-threatening acute illnesses. The society helps to set the standards for prevention, treatment, and control of these serious diseases.

Medical information

For product information about Zemaira, please contact CSL Behring Medical Information at:

Phone: 800-504-5434
Fax: 610-878-4550
E-mail: Contact Us

You may also send correspondence by mail to the following address:

Medical Information
North American Headquarters
CSL Behring
PO Box 61501
1020 First Avenue
King of Prussia, PA 19406 USA

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. No clinical data are available demonstrating the effect of augmentation therapy with Zemaira or any A1-PI product on the progression of emphysema in A1-PI deficiency.

Zemaira is not indicated for lung disease patients in whom severe A1-PI deficiency has not been established.

Zemaira is contraindicated in patients with a history of severe systemic reactions to the product or to A1-PI protein, including anaphylaxis. Due to the risk of severe hypersensitivity, Zemaira is also contraindicated in immunoglobulin A-deficient patients with antibodies against IgA.

Use caution in administering Zemaira to patients who have experienced anaphylaxis or severe systemic reactions to another A1-PI product. Patients with selective or severe IgA deficiency can develop antibodies to IgA and are at greater risk of such reactions. If anaphylactic or severe anaphylactoid reactions occur during infusion, discontinue immediately.

In pre-licensure clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, asthenia, increased cough, fever, injection-site hemorrhage, rhinitis, sore throat, and vasodilation.

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.

© 2017 CSL Behring LLC. The product information presented on this site is intended for US residents only. ZMR03-13-0022(3) 6/2015